Larson DL - Search Results

1

Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.

Subramanian G, Paterlini MG, Larson DL, Portoghese PS, Ferguson DM. Subramanian G, et al. Among authors: larson dl. J Med Chem. 1998 Nov 19;41(24):4777-89. doi: 10.1021/jm9803166. J Med Chem. 1998. PMID: 9822548

2

Opioid agonist and antagonist activities of morphindoles related to naltrindole.

Portoghese PS, Larson DL, Sultana M, Takemori AE. Portoghese PS, et al. Among authors: larson dl. J Med Chem. 1992 Nov 13;35(23):4325-9. doi: 10.1021/jm00101a009. J Med Chem. 1992. PMID: 1333013

3

Persistent binding of fatty acyl derivatives of naltrexamine to opioid receptors.

Portoghese PS, Garzon-Aburbeh A, Larson DL. Portoghese PS, et al. Among authors: larson dl. J Med Chem. 1991 Jul;34(7):1966-9. doi: 10.1021/jm00111a007. J Med Chem. 1991. PMID: 1648619

4

Hybrid bivalent ligands with opiate and enkephalin pharmacophores.

Portoghese PS, Larson DL, Ronsisvalle G, Schiller PW, Nguyen TM, Lemieux C, Takemori AE. Portoghese PS, et al. Among authors: larson dl. J Med Chem. 1987 Nov;30(11):1991-4. doi: 10.1021/jm00394a010. J Med Chem. 1987. PMID: 2444704

5

Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.

Botros S, Lipkowski AW, Larson DL, Stark PA, Takemori AE, Portoghese PS. Botros S, et al. Among authors: larson dl. J Med Chem. 1989 Sep;32(9):2068-71. doi: 10.1021/jm00129a009. J Med Chem. 1989. PMID: 2475628

6

Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity.

Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE. Portoghese PS, et al. Among authors: larson dl. J Med Chem. 1988 Apr;31(4):836-41. doi: 10.1021/jm00399a026. J Med Chem. 1988. PMID: 2832604

7

Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine.

Larson DL, Hua M, Takemori AE, Portoghese PS. Larson DL, et al. J Med Chem. 1993 Nov 12;36(23):3669-73. doi: 10.1021/jm00075a023. J Med Chem. 1993. PMID: 8246236

8

Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors.

Bolognesi ML, Ojala WH, Gleason WB, Griffin JF, Farouz-Grant F, Larson DL, Takemori AE, Portoghese PS. Bolognesi ML, et al. Among authors: larson dl. J Med Chem. 1996 Apr 26;39(9):1816-22. doi: 10.1021/jm950807f. J Med Chem. 1996. PMID: 8627605

9

7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.

Ohkawa S, DiGiacomo B, Larson DL, Takemori AE, Portoghese PS. Ohkawa S, et al. Among authors: larson dl. J Med Chem. 1997 May 23;40(11):1720-5. doi: 10.1021/jm9700880. J Med Chem. 1997. PMID: 9171881

10

7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.

Fang X, Larson DL, Portoghese PS. Fang X, et al. Among authors: larson dl. J Med Chem. 1997 Sep 12;40(19):3064-70. doi: 10.1021/jm970283e. J Med Chem. 1997. PMID: 9301669

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page